A study led by Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine (FL, USA) seeks to understand how AI can improve breast cancer screening. The Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography (PRISM) trial will examine hundreds of thousands of mammograms to “assess AI’s true impact”

Despite huge investments in research, breast cancer remains a leading cause of mortality in US women. Routine mammography has increased the diagnosis of early-stage cancer, but the increased incidence of false positives can lead to unnecessary testing, anxiety and higher costs.

“As the first major randomized trial of AI in breast cancer screening in the US, this study represents a pivotal step,” commented Jose Net, University of Miami Miller School of Medicine and co-principal investigator of the study. “Our goal is to rigorously and objectively assess AI’s impact, identifying who benefits and who may not.”